Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise against staph blood infections

NCT ID NCT05184764

Disease control Sponsor: Armata Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called AP-SA02, given through a vein, along with standard antibiotics for adults with a Staph blood infection. The main goal was to check if the combination is safe and tolerable. Researchers also looked at whether it helped clear the infection faster. The study involved 56 participants and has been completed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

56 people

The number who actually took part.

Started

Apr 2022

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * A hospitalized female or male ≥ 18 years old * Positive blood culture for Staphylococcus aureus (SA) * Source of SA infection controlled, or a plan for source control, if relevant * Not pregnant or breastfeeding and is not of reproductive potential or agrees to use contraception if or reproductive potential Key Exclusion Criteria: * Concomitant growth of organisms besides SA * Left-sided infectious endocarditis by modified Duke criteria * Known or suspected brain abscess or meningitis * Known allergy to phage products

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacteremia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis staphylococcal infection staphylococcus aureus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacteremia Bacteremia due to staphylococcus aureus Bacteremia staph Staphylococcus aureus Staphylococcus aureus bacteremia

Contacts and locations

Locations

  • Banner University Medical Center

    Tucson, Arizona, 85719, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, 30308, United States

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21218, United States

  • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center

    Torrance, California, 90502, United States

  • Methodist Hospital Research Institute - Houston

    Houston, Texas, 77030, United States

  • Monash Health

    Clayton, Australia

  • Montefiore Medical Center

    The Bronx, New York, 10467, United States

  • Regional One Healthcare

    Memphis, Tennessee, 38103, United States

  • Rhode Island Hospital

    Providence, Rhode Island, 02903, United States

  • Rocky Mountain Regional VA Medical Center

    Aurora, Colorado, 80045, United States

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Royal Melbourne Hospital

    Melbourne, Australia

  • The Alfred Hospital

    Melbourne, Australia

  • The Jamaica Hospital Medical Center

    Jamaica, New York, 11418, United States

  • Tufts Medical Center

    Boston, Massachusetts, 02111, United States

  • University of California, Los Angeles (UCLA) - Medical Center

    Los Angeles, California, 90095, United States

  • University of California, San Diego (UCSD) - Medical Center

    La Jolla, California, 92037, United States

  • University of Florida (UF) - Division of Infectious Disease

    Gainesville, Florida, 32610, United States

  • University of Florida - Jacksonville

    Jacksonville, Florida, 32209, United States

  • University of Michigan

    Ann Arbor, Michigan, 48103, United States

  • University of North Carolina - Chapel Hill School of Medicine

    Chapel Hill, North Carolina, 27599, United States

  • University of South Florida

    Tampa, Florida, 33620, United States

  • University of Southern California Keck School of Medicine

    Los Angeles, California, 90033, United States

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27157, United States

  • Westmead Hospital

    Westmead, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.